Pedro Esbrit

Dr. Pedro Esbrit

Emeritus Investigator, IIS-Fundación Jiménez Díaz, Avda. Reyes Católicos 2, 28040 Madrid, Spain
orcid

Research Focus & Metrics

Academic Career Length

37Years (1990-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 August 2018 in Nanomaterials
Verified
Journal Article
Open access
PDF file
RPRebeca Pérez
Rebeca Pérez
Sandra Sanchez-SalcedoSandra Sanchez-Salcedo
Sandra Sanchez-Salcedo
DLDaniel Lozano
Daniel Lozano
CHClara Heras
Clara Heras
Pedro EsbritPedro Esbrit
Pedro Esbrit
Antonio J.  SalinasAntonio J. Salinas
Antonio J. Salinas
Mesoporous Bioactive Glasses (MBGs) are a family of bioceramics widely investigated for their putative clinical use as scaffolds for bone regeneration. Their outstanding textural properties allow for high bioactivity when compared with other bioactive materials. Moreover, their great pore volumes allow these glasses to be loaded with a wide range of biomolecules to stimulate new bone formation. In this study, an MBG with a composition, in mol%, of 80% SiO2–15% CaO–5% P2O5 (Blank, BL) was compared with two analogous glasses containing 4% and 5% of ZnO (4ZN and 5ZN) before and after impregnation with osteostatin, a C-terminal peptide from a parathyroid hormone-related protein (PTHrP107-111). Zn2+ ions were included in the glass for their bone growth stimulator properties, whereas osteostatin was added for its osteogenic properties. Glasses were characterized, and their cytocompatibility investigated, in pre-osteoblastic MC3T3-E1 cell cultures. The simultaneous additions of osteostatin and Zn2+ ions provoked enhanced MC3T3-E1 cell viability and a higher differentiation capacity, compared with either raw BL or MBGs supplemented only with osteostatin or Zn2+. These in vitro results show that osteostatin enhances the osteogenic effect of Zn2+-enriched glasses, suggesting the potential of this combined approach in bone tissue engineering applications.

31 January 2017 in Journal of Cellular Physiology
Verified
Journal Article
Open access
PDF file
MMMarta Maycas
Marta Maycas
MPMaría Teresa Portolés
María Teresa Portolés
MMMaría Concepción Matesanz
María Concepción Matesanz
IBIrene Buendía
Irene Buendía
JLJavier Linares
Javier Linares
AGArancha R Gortazar
Arancha R Gortazar
Diabetes mellitus (DM) induces bone deterioration, while mechanical stimulation promotes osteocyte‐driven bone formation. We aimed to evaluate the interaction of acute exposure (24 h) to high glucose (HG) with both the pro‐survival effect conferred to osteocytic MLO‐Y4 cells and osteoblastic MC3T3‐E1 cells by mechanical stimulation and the interaction of these cells with osteoclast precursor RAW264.7 cells. We found that 24 h of HG (25 mM) pre‐exposure prevented both cell survival and ERK and β‐catenin nuclear translocation upon mechanical stimulation by fluid flow (FF) (10 min) in both MLO‐Y4 and MC3T3‐E1 cells. However, migration of RAW 264.7 cells was inhibited by MLO‐Y4 cell‐conditioned medium (CM), but not by MC3T3‐E1 cell‐CM, with HG or FF. This inhibitory effect was associated with consistent changes in VEGF, RANTES, MIP‐1α, MIP‐1β MCP‐1, and GM‐CSF in MLO‐Y4 cell‐CM. RAW264.7 proliferation was inhibited by MLO‐Y4 CM under static or HG conditions, but it increased by FF‐CM with or without HG. In addition, both FF and HG abrogated the capacity of RAW 264.7 cells to differentiate into osteoclasts, but in a different manner. Thus, HG‐CM in static condition allowed formation of osteoclast‐like cells, which were unable to resorb hydroxyapatite. In contrast, FF‐CM prevented osteoclastogenesis even in HG condition. Moreover, HG did not affect basal RANKL or IL‐6 secretion or their inhibition induced by FF in MLO‐Y4 cells. In conclusion, this in vitro study demonstrates that HG exerts disparate effects on osteocyte mechanotransduction, and provides a novel mechanism by which DM disturbs skeletal metabolism through altered osteocyte‐osteoclast communication.

15 January 2022 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
Antonio J.  SalinasAntonio J. Salinas
Antonio J. Salinas
Pedro EsbritPedro Esbrit
Pedro Esbrit
Throughout her impressive scientific career, Prof. María Vallet-Regí opened various research lines aimed at designing new bioceramics, including mesoporous bioactive glasses for bone tissue engineering applications. These bioactive glasses can be considered a spin-off of silica mesoporous materials because they are designed with a similar technical approach. Mesoporous glasses in addition to SiO2 contain significant amounts of other oxides, particularly CaO and P2O5 and therefore, they exhibit quite different properties and clinical applications than mesoporous silica compounds. Both materials exhibit ordered mesoporous structures with a very narrow pore size distribution that are achieved by using surfactants during their synthesis. The characteristics of mesoporous glasses made them suitable to be enriched with various osteogenic agents, namely inorganic ions and biopeptides as well as mesenchymal cells. In the present review, we summarize the evolution of mesoporous bioactive glasses research for bone repair, with a special highlight on the impact of Prof. María Vallet-Regí´s contribution to the field.

21 December 2021 in Biomolecules
Verified
Journal Article
Open access
PDF file
MPMarina Ribeiro Paulini
Marina Ribeiro Paulini
IRIván Nadir Camal Ruggieri
Iván Nadir Camal Ruggieri
MRMelina Ramallo
Melina Ramallo
MAMatilde Alonso
Matilde Alonso
JRJose Carlos Rodriguez-Cabello
Jose Carlos Rodriguez-Cabello
SFSara Feldman
Sara Feldman
The increase in fracture rates and/or problems associated with missing bones due to accidents or various pathologies generates socio-health problems with a very high impact. Tissue engineering aims to offer some kind of strategy to promote the repair of damaged tissue or its restoration as close as possible to the original tissue. Among the alternatives proposed by this specialty, the development of scaffolds obtained from recombinant proteins is of special importance. Furthermore, science and technology have advanced to obtain recombinant chimera’s proteins. This review aims to offer a synthetic description of the latest and most outstanding advances made with these types of scaffolds, particularly emphasizing the main recombinant proteins that can be used to construct scaffolds in their own right, i.e., not only to impregnate them, but also to make scaffolds from their complex structure, with the purpose of being considered in bone regenerative medicine in the near future.

17 December 1999 in Clinica Chimica Acta
Verified
Journal Article
Closed access
JMJ.L Motellón
J.L Motellón
FJF.Javier Jiménez
F.Javier Jiménez
FMF de Miguel
F de Miguel
MJM.J Jaras
M.J Jaras
ADA Dı́az
A Dı́az
Pedro EsbritPedro Esbrit
Pedro Esbrit

1 August 2000 in Nephrology Dialysis Transplantation
Verified
Journal Article
Open access
PDF file
Pedro EsbritPedro Esbrit
Pedro Esbrit
JEJesús Egido
Jesús Egido
Parathyroid hormone (PTH)‐related protein (PTHrP) was initially isolated from tumours associated with humoural hypercalcaemia of malignancy [1]. Both PTH and PTHrP share homology in their N‐terminal region, and bind to the type 1 PTH/PTHrP receptor (PTHR), first cloned in osteoblasts and renal tubular cells, activating both adenylate cyclase and phospholipase C/protein kinase C [2]. However, while PTH is a regulator of mineral homeostasis, acting mainly on bone and kidney, PTHrP is now known to be widely expressed in non‐malignant foetal and adult tissues [3]. Furthermore, PTHrP post‐translational processing generates various fragments, including the PTH‐like region and other mid‐ and C‐terminal domains lacking PTH homology [4,5]. These fragments, interacting with specific receptors, appear to act as autocrine/paracrine regulators of cell growth and/or differentiation, at least in some tissues [1,3]. Although knowledge of the physiological role of PTHrP and its fragments in the kidney is in its infancy, the present review focuses on recent hypotheses regarding the putative actions of this protein as a complex renal cytokine.